The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...

I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called ...

Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...

Dr. Duffy says asthma, reflux, post-nasal drip, and drugs like ACE inhibitors for blood pressure, cause the most coughs. GERD, or reflux, can cause coughing, although coughing can also cause GERD.

Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. The biopharmaceutical company posted a loss of $11.4 million, or 11 cents ...

Trevi Therapeutics (TRVI) surges 40% premarket as Haduvio proves effective in reducing chronic coughing in trials.

The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...

“That cough’s going to give me a heart attack!” quipped one father, a doctor who had accompanied his young son to a lesson.